While Menarini Group/Stemline Therapeutics, Inc.’s leading oral selective estrogen receptor degrader (SERD) Orserdu has got off to a strong start following its February launch for breast cancer, newcomer Olema Pharmaceuticals, Inc. is hoping that its similar offering, palazestrant, will be able to go even further, based on early data in a number of clinical settings.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?